Overig
Practice questions Tumor Immunology
- Instelling
- Vrije Universiteit Amsterdam (VU)
Here are 25 practice questions based on my lecture notes. These questions test if you fully understand the study material.
[Meer zien]Voorbeeld 2 van de 5 pagina's
Voorbeeld 2 van de 5 pagina's
In winkelwagengesponsord bericht van onze partner
Voorbeeld van de inhoud
Practice questions:Advanced Tumor Immunology Concepts
1. How do tumors leverage the immunosuppressive functions of regulatory T-cells (T-reg) and
myeloid-derived suppressor cells (MDSCs) to evade immune surveillance, and what are the
molecular mechanisms involved?
2. Describe the process of cross-dressing in dendritic cells (DCs) and explain its implications in
tumor immunology.
3. Explain the mechanisms by which tumors reduce MHC-I expression and the role of NK cells in
compensating for this immune evasion strategy.
Tumor Evasion and Immune Editing
4. How does the concept of immune editing explain the transition from tumor elimination to
equilibrium and eventually to immune escape? Provide examples of immune evasion
mechanisms that tumors develop over time.
5. Discuss the role of co-stimulatory and inhibitory signals in T-cell activation and how tumors
exploit these pathways to induce T-cell anergy.
6. How do tumors manipulate macrophages to favor an immunosuppressive (M2) phenotype,
and what are the consequences of this shift for tumor progression?
Immunotherapy and Tumor Vaccines
7. What is the rationale behind using checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 in
combination, and what are the limitations of this approach?
8. Explain the concept of autologous dendritic cell (DC) vaccination in cancer therapy, including
the key challenges associated with this approach.
9. In CAR-T cell therapy, what are the advantages and challenges of targeting solid tumors
compared to hematological malignancies?
Advanced Tumor Antigen Recognition
10. Differentiate between tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) in
the context of cancer immunotherapy. Why are TSAs considered more ideal targets?
11. Describe the role of neoantigens in the success of immune checkpoint blockade therapies.
12. How does cross-presentation by dendritic cells contribute to the activation of cytotoxic T-
lymphocytes (CTLs) in the tumor microenvironment?
Glycosylation and Tumor Immunology
13. What is the role of aberrant glycosylation in tumor immune evasion, and how do lectins such
as Siglecs contribute to this process?
14. How can targeting tumor-associated glycan structures be used as a therapeutic strategy in
cancer immunotherapy?
Myeloid-Derived Suppressor Cells (MDSCs)
15. Explain the transcriptional regulation of MDSCs in the tumor microenvironment and how it
leads to immune suppression.
16. How do MDSCs contribute to tumor metastasis, and what are the mechanisms involved in
this process?
, Virotherapy and Oncolytic Viruses
17. What mechanisms allow oncolytic viruses to selectively replicate in tumor cells, and how
does this strategy enhance anti-tumor immunity?
18. How can combining oncolytic virotherapy with immune checkpoint inhibitors enhance
therapeutic outcomes in cancer patients?
Advanced Diagnostic Techniques
19. How does liquid biopsy compare to traditional tissue biopsy in terms of identifying prognostic
and predictive biomarkers for cancer?
20. Discuss the advantages and limitations of using single-cell RNA sequencing in tumor
immunology research.
Immune Modulation in Cancer Therapy
21. How does radiotherapy-induced immunogenic cell death enhance the efficacy of immune
checkpoint blockade?
22. Explain the STING (Stimulator of Interferon Genes) pathway and its role in the anti-tumor
immune response following DNA damage in cancer cells.
Advanced Immunotherapy Strategies
23. How does the tumor microenvironment influence the efficacy of CAR-T cell therapy, and what
strategies are being developed to overcome these challenges?
24. What role does the gut microbiome play in modulating the response to cancer
immunotherapy, and how could microbiome manipulation be used as a therapeutic strategy?
25. How does the combination of bispecific T-cell engagers (BiTEs) and oncolytic viruses enhance
tumor cell targeting and destruction?
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper sweerstand. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €4,36. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 85443 samenvattingen verkocht
Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen